As a therapeutic radiopharmaceutical, 177Lu-FAP-2286 showed similar biodistribution by SPECT/CT as the imaging agent 68Ga-FAP-2286, and likewise, it had significant tumor uptake and long retention that appeared to improve symptoms manifested by pain reduction in 3 patients with advanced disease (51). The gene discussed is FAP; the disease is neoplasm.